PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy

Cancer immunotherapy has greatly advanced in recent years, and PD-1/PD-L1 blocking therapy has become a major pillar of immunotherapy. Successful clinical trials of PD-1/PD-L1 blocking therapies in cancer treatments have benefited many patients, which promoted the Food and Drug Administration (FDA)...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Long, Zhang, Qi, Zhang, Rongxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994550/
https://www.ncbi.nlm.nih.gov/pubmed/29951336
http://dx.doi.org/10.20892/j.issn.2095-3941.2017.0086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994550/
https://www.ncbi.nlm.nih.gov/pubmed/29951336
http://dx.doi.org/10.20892/j.issn.2095-3941.2017.0086

Ejemplares similares